C ranial base meningiomas typically involve major cerebral vessels and cranial nerves. To prevent death and complications, it is not always possible to perform a complete resection; 1, 14 consequently, tumor recurrence after surgery is common. 24, 32 We must consider that the quality of life of patients and their caregivers may worsen after the surgical treatment of a skull base meningioma. 20 Radiosurgery for skull base meningiomas has been reported to have a low rate of complications with a high rate of tumor growth control. 4, 5, 15, 18, 22, 25, 30 The long-term results of radiosurgery for skull base meningiomas have been reported. 17, 34 We have reported on the usefulness of low-dose radiosurgery for skull base meningiomas in a prior publication. 10 We studied the usefulness of low-dose radiosurgery in tumors close to a critical organ (such as the optic nerve), 8 large recurring tumors, residual tumor volume after surgery, or in tumors that are difficult to resect because of their location or because of the patient's condition. 9 In the present study, we provide the data from an expanded postsurgical follow-up period and analyze the outcome in patients who underwent low-dose GKS for skull base meningiomas.
Methods
Between January 1994 and December 2001, 125 consecutive patients with benign skull base meningiomas underwent GKS (Elekta Instrument AB) at our institution. Excluded form this study were 13 patients who received radiosurgical doses > 12 Gy (range 13-16 Gy) and 4 patients who were lost to follow-up. Written informed consent was obtained for each patient (either from the patient or his or her responsible guardian). The median age of these patients was 57 years (range 18-81 years), and there were 91 women and 17 men. Included in this analysis of long-term follow-up data were all patients reported on previously. [8] [9] [10] After radiosurgery, patients were scheduled to undergo clinical evaluations and serial contrast-enhanced MR imaging every 6 months over the next 3 years, and then every 1 or 2 years after the initial follow-up period. Telephone interviews with patients and/or referring physicians were conducted to confirm the clinical status of each patient when such information was not otherwise available. Malignant transformation was diagnosed based on the tumor's histological diagnosis or the aggressiveness of its course at the time of recurrence. Treatment failure was defined as local failure (regrowth in the treatment field), marginal failure (tumor recurrence close to the treatment field), and out-of-field recurrence (tumor recurrence away from the treatment field). Tumor growth control rates were determined using the Kaplan-Meier survival analysis. 13 
Radiosurgical Procedure
After the injection of a local anesthetic, the stereotactic frame was attached (Leksell model G; Elekta Instruments AB). Supplemental intravenous sedation was provided as needed (1.25-2.50 mg midazolam). Anodyne ointment was applied for the screw insertion procedure, and patients also received intravenous anodyne (50 mg). Thin-slice MR images were obtained at 1.5-or 3-mm thickness. Radiosurgical dose planning was performed from January to July 1994 with the Kula system (Elekta Instruments AB), and from July 1994 to December 2001 using GammaPlan (Elekta Instruments AB).
Radiation Dosimetry
The tumor volume ranged from 1.7 to 55.3 cm 3 (median 8.1 cm 3 ). The median radiation dose delivered to the tumor center was 24 Gy (range 15-24 Gy), and the median dose delivered to the tumor margin was 12 Gy (range 8-12 Gy). The median isodose to the tumor margin was 50% (range 30-80%). The overall dose selection was adjusted according to the location and volume of each tumor.
Ten patients with large-volume tumors were treated with 2-staged radiosurgery (volume fraction), based on our experience with treating tumors of this size. 8 The median tumor diameter in this group was 42.4 mm (range 35.9-47.2 mm) and the median tumor volume was 38. 
Results
The tumor was located in the cavernous sinus in 32 patients, the petroclival junction in 20 patients, the cerebellopontine angle in 16, the petrocavernous segment of the internal carotid artery in 13, the sphenoid wing in 9, the tuberculum sella in 6, the clivus in 5, the foramen magnum in 3, and the jugular foramen and frontal base in 2 patients each. Sixty-two patients (57%) had undergone at least 1 tumor resection prior to radiosurgery, 21 patients (19%) had undergone > 1 resection, and 46 patients (43%) had previously received primary radiosurgery for skull base meningiomas based on neuroradiological diagnosis; no patients had been treated with previous radiation therapy. The presenting neurological symptoms are shown in Table 1 . Trigeminal (25%) and abducent nerve (17%) deficits were the most common neurological symptoms at the time of radiosurgery; however, 20% of patients were asymptomatic prior to the procedure.
Treatment Response
The mean duration of follow-up was 86.1 months (range 20-144 months). Overall, tumor volume decreased in 50 patients (46%; Fig. 1 ), remained stable in 51 patients (47%), and increased (local failure) in 7 patients (6%). Among the patients with local failure, 2 patients suffered intratumoral bleeding and 3 had malignant changes. Another 11 patients experienced tumor recurrence outside the treatment field; among these, 5 (5%) had marginal failures, and 6 (5.6%) experienced a distant recurrence of their tumors. Malignant transformations occurred in 7 patients (6%; Fig. 2 ).
Tumor growth control was achieved in 90 patients (83%). The actuarial tumor control rate for patients, including malignant transformation and out-of-field recurrence, was 93% at 5 years, and 83% at 10 years (Fig. 3) . The mean time to treatment failure after radiosurgery was 81.8 months (range 20-144 months). Among patients with treatment failure, 9 patients underwent repeated radiosurgery and 1 patient had radiosurgery and resection. Using the chi-square test of independence, we found that patient age, sex, prior surgery status, and radiation dose to the tumor margin were not statistically significant factors in predicting tumor recurrence.
Clinical Outcome
Clinical improvement was defined as resolution of neurological or cranial nerve deficits, or a reduction in preoperative symptoms. Neurological status improved in 16 patients, remained stable in 54, and deteriorated in 19. Of the 19 patients who had clinical deterioration, there were 2 subgroups: those with adverse effects of radiation, and those who experienced tumor progression despite radiosurgery. In 9 patients deterioration was due to tumor growth, and in 9 it was due to radiation injury; 1 patient's condition worsened due to intracerebral hemorrhage unrelated to the tumor. After radiosurgery, of the 86 patients with preoperative neurological deficits (135 deficits total), 18 deficits improved or disappeared, 109 remained unchanged, and eventual worsening was seen in 8. Among the 22 patients without preoperative symptoms, 19 patients exhibited no symptoms postoperatively, while 3 patients had worsened symptoms ( Table 2) . 
Adverse Effects
Adverse effects of radiation were observed in 9 patients (Table 3) . There was permanent injury in 7 patients (6%) and transient injury in 2 (2%). The transient radiation injuries included temporal lobe edema at 1 month postradiosurgery (in 1 patient) and a convulsive attack at 4-months postsurgery in another patient who also had slightly worsened optic nerve function at 16 months postoperatively.
The 7 patients who experienced permanent radiation injuries included 1 patient who suffered transient facial spasms 6-12 months postsurgery, temporal lobe edema from 24 months after the procedure, and tumor recurrence at 42 months after radiosurgery. One patient experienced slight worsening of a preexisting oculomotor nerve palsy at 42 months, and in 1 patient there was worsening of a preexisting facial palsy at 7 months after radiosurgery. One patient suffered perifocal edema 3 months after radiosurgery, continued with steroid hormone treatment, and had worsening of trigeminal sensory disturbance at 66 months. One patient with sphenoid wing meningiomas suffered hemiparesis due to occlusion of a middle cerebral artery perforating vessel at 32 months after radiosurgery. A patient with cerebellopontine angle meningiomas suffered worsening of tinnitus and vertigo at 30 months after radiosurgery. One patient experienced worsening of a previously improved trigeminal neuropathy at 36 months after radiosurgery. All of these events were associated with the presence of clinical or neurological deterioration in the absence of tumor growth. The mean time to clinical deterioration was 22 months (range 1-66 months).
Twelve patients died during the follow-up period. Six deaths were related to meningioma: 4 patients had tumor growth with malignant changes, 1 patient had intratumoral bleeding, and 1 experienced worsening of an intracranial condition related to the brain tumor. Other patient deaths were attributed to other disease processes, including cerebrovascular disease (in 2 patients), worsen- ing of a general condition due to old age (91 years old; 1 patient), renal cell carcinoma (1 patient), complications of diabetes mellitus (1 patient), and lung cancer (1 patient).
Discussion
Microsurgery is considered the gold standard therapy for skull base meningiomas. Resection of these tumors has historically carried a high rate of complications. Recently, radiosurgery has been applied to cranial base meningiomas after incomplete resection or even concomitantly with resection. 4 Several authors have reported their results with radiosurgery for skull base meningiomas (Table 4) . Tumor control has been reported to be 92-100% in patients with skull base meningiomas. 4, 5, 18, 22, 23, 25, 31, 34 Recent long-term (> 5 year) follow-up data show tumor growth control of 92-98%.
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Radiosurgical Dose and Tumor Control
Ganz and colleagues 6 recommended a dose > 12 Gy to the tumor margin because patients who received < 12-Gy doses showed a 40% tumor growth rate during a 1-year follow-up period. Shin et al. 31 reported that a 14-Gy dose produced no recurrence; however, in patients who received 10-12 Gy, 20% of lesions recurred. The minimum effective radiation dose for skull base meningiomas has been reported as 13-17 Gy 4, 5, 15, 18, 22, 25, 30, 34 with only a few authors recommending low-dose treatment. 28 We used a median dose of 12 Gy. If control over local tumor growth is not obtained because of low-dose treatment, this dosing regimen will not be acceptable. Our results show local recurrence in 7 patients (6%), recurrence outside the treatment field in 11 (10%), and malignant transformation in 7 (determined based on histological or radiological behavior). We observed a 5-year actuarial tumor control rate of 93% and a 10-year control rate of 83%. In comparing our results with those of others with regard to tumor growth control, our tumor growth control rate is the same despite our use of low-dose radiosurgery.
Some authors have reported that the tumor growth remained controlled 5-10 years after radiosurgery; 16, 34 this means that late recurrence is rare. However, Kobayashi et al. 15 reported tumor recurrence during 7 years of longterm follow-up. We must consider marginal failure and malignant changes when discussing tumor growth control of meningiomas.
Marginal Failure
Lee et al. 22 suspected that previously resected tumors might be more difficult to delineate on radiological examination due to postoperative meningeal enhancements or fat signals that may be mistaken for tumor tissue. Zachenhofer and associates 34 suggested that tumor regrowth was always found outside the radiosurgical volume and that this marginal error may be attributed to microscopic remnants of tumor cells within the adjacent dura mater that remain outside the radiosurgical target. We could not find a relationship between failure rate and whether patients had undergone resection prior to GKS. The marginal failure rate in the operative group was 6.5% (4/62 patients) and 8.7% (4/46 patients) in the group that did not undergo surgery. We did not cover the dural tail during radiosurgical dose planning. Whether or not the dural tail included tumor cells in our patients was not determined. Some authors have reported the presence of tumor cells in the dural tail 7 while others did not find any.
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Malignant Changes
Malignant transformation of benign meningiomas must also be considered in evaluating treatment outcome. In their clinical study, Al-Mefty et al. 2 reported that up to 2% of benign meningiomas transform into malignant meningiomas, and others have reported that 28.5% of all recurrent benign meningiomas will be found to be atypical or anaplastic. 11, 12 Malignant transformation was observed in 7 patients (6.5%) in the present study. Our patients had a higher incidence of malignant changes than those in other radiosurgical series. We consider malignant transformation after radiosurgery to be a result of the natural course of the disease and not triggered by radiosurgery.
Radiation Dose for Cranial Nerves
The sensitivity of the cranial nerves to radiosurgery varies, and the optic nerve is thought to be the most sensitive. 26 Leber et al. 21 reported that the optic nerve could be irradiated with < 10 Gy without complications. However, a radiation dose of 10-15 Gy produced a 26.5% risk of optic neuropathy. Tumors close to or compressing the optic apparatus could not be controlled with radiation because of the difficulty of providing a sufficient dose to the tissue without harming the optic nerve. Radiosurgery is indicated when there is no chiasm or optic nerve compression and the tumor is > 5 mm from the chiasm and optic nerve. 31 Morita et al. 26 adopted a policy of allowing short segments of the visual pathways to be dosed with 12-16 Gy. Stafford et al. 33 also reported using a higher dose (12 Gy) for small portions of the optic apparatus, with no optic neuropathy seen secondary to radiation injury. We reduced the tumor marginal dose to 8-10 Gy for tumors that adhered to or compressed the optic apparatus and maintained a small, nonradiated distance from the optic apparatus. Tumor tissue close to the optic apparatus could be irradiated with < 6 Gy. In our experience, growth control can be achieved in tumors that compress or are attached to the optic apparatus if most of the tumor tissue receives a sufficient dose of radiation; the entire tumor mass does not require the same dose. 8 In some patients with tumor compression or attachment to the optic apparatus, we used a relatively low dose (8-10 Gy) at the tumor margin and a higher dose (12 Gy) on a small part of the optic apparatus.
Motor nerve function is little changed by radiosurgery; Leber et al. 21 reported that 22% of their treated skull base meningiomas had recovery of the oculomotor nerve (mean dose 12.5 Gy), while Morita et al. 26 reported that 16% of their patients experienced oculomotor nerve improvement. Our results showed that 1 patient (7%) improved and 2 patients worsened (14%).
The trigeminal nerve was very sensitive to radiosurgery; Lee et al. 22 reported that 4% of their patients (6/159) developed trigeminal neuropathy, with 4 of these deficits becoming permanent. Chang et al. 3 reported secondary facial pain after radiosurgery; although 86% of their patients initially received pain relief, half of these individuals reported pain recurrence during the follow-up period. Morita et al. 26 reported on 9 cases of radiation-induced, permanent trigeminal neuropathy (10.5% of the nerves at risk) after a latent interval of 2-7 months. They noted that patients treated with a radiation dose > 19 Gy had a high incidence of trigeminal neuropathy. Leber et al. 21 reported no new trigeminal neuropathy when a mean dose of 12.9 Gy was used. In our patients, 3 of 27 patients (11%) experienced worsening trigeminal neuropathy, 7 improved, and in 3 patients, symptoms worsened but there was no new trigeminal neuropathy. We believe that the low rate of trigeminal neuropathy in our patients is related to the low radiation doses used.
Other Complications
Three of our patients (2.8%) suffered intratumoral bleeding. Kwon et al. 19 reported 3 of 173 patients (1.7%) suffered intratumoral bleeding after radiosurgery, and noted that the risk of spontaneous intratumoral bleeding in meningiomas is 1.3-2.7%. This finding is not unduly high in comparison with the natural incidence of intratumoral bleeding of meningiomas. We also think that intratumoral bleeding after radiosurgery is a natural occurrence in patients with skull base meningiomas.
Large-Volume Tumors
We treated large-volume tumors (> 4-cm diameter) with staged radiosurgery in 10 patients, as previously described by Pendl and associates. 29 Our strategy for staged radiosurgery was to apply low doses to the tumor margin and volume fraction. 9 We used staged radiosurgery in patients with residual tumors after resection or in patients with large-volume tumors whom the surgeon considered likely to have complications after surgery (depending on the tumor location and patient's condition). We used staged radiosurgery in 10 patients: in 8 this resulted in good tumor control, and 2 experienced tumor regrowth (1 had a malignant change), but no patients suffered radiation injury.
Conclusions
Our results support the long-term benefits of low-dose radiosurgery in the management of skull base meningiomas. We consider low-dose radiosurgery for skull base meningiomas to be most useful in tumors close to critical organs (such as the optic nerves) and in large-volume tumors. We must be aware of the possibility of treatment failure, defined as local failure, marginal failure, and malignant transformation; however, this may be the natural course of meningiomas and not related to radiosurgery.
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